Foundation Medicine Inc (NASDAQ:FMI) CEO Troy Cox sold 9,012 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $67.22, for a total transaction of $605,786.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Troy Cox also recently made the following trade(s):
- On Wednesday, February 7th, Troy Cox sold 26,713 shares of Foundation Medicine stock. The stock was sold at an average price of $70.13, for a total transaction of $1,873,382.69.
Shares of Foundation Medicine Inc (FMI) traded up $1.70 during mid-day trading on Tuesday, reaching $76.60. 358,840 shares of the company’s stock traded hands, compared to its average volume of 271,607. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03. Foundation Medicine Inc has a 52 week low of $22.40 and a 52 week high of $78.00. The stock has a market cap of $2,715.32, a PE ratio of -17.14 and a beta of -0.03.
Hedge funds have recently modified their holdings of the business. Fiduciary Trust Co. purchased a new position in Foundation Medicine in the 4th quarter valued at approximately $205,000. BlueCrest Capital Management Ltd acquired a new stake in shares of Foundation Medicine in the 4th quarter valued at $239,000. Financial Advocates Investment Management acquired a new stake in shares of Foundation Medicine in the 4th quarter valued at $239,000. UBS Asset Management Americas Inc. acquired a new stake in shares of Foundation Medicine in the 4th quarter valued at $241,000. Finally, Raymond James & Associates acquired a new stake in shares of Foundation Medicine in the 4th quarter valued at $244,000. 30.86% of the stock is owned by institutional investors.
A number of equities analysts recently weighed in on FMI shares. Goldman Sachs Group started coverage on shares of Foundation Medicine in a research report on Monday, January 29th. They set a “neutral” rating and a $73.00 price objective for the company. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. Zacks Investment Research cut shares of Foundation Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Finally, Cowen started coverage on shares of Foundation Medicine in a research report on Thursday, February 15th. They set an “outperform” rating and a $90.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $59.80.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Foundation Medicine Inc (FMI) CEO Sells 9,012 Shares of Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/20/insider-selling-foundation-medicine-inc-fmi-ceo-sells-9012-shares-of-stock.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.